摘要
脑胶质瘤是临床最常见的原发性颅内恶性肿瘤,尤以胶质母细胞瘤预后最差。近年来,靶向免疫检查点的免疫治疗在多种实体肿瘤中展现出良好疗效,成为胶质瘤药物治疗领域的潜在突破口,受到国内外神经外科和神经肿瘤科医师的关注。通过综述免疫检查点分子及抑制剂临床研究进展,介绍免疫治疗在胶质瘤领域的研究现状,以期对我国胶质瘤免疫治疗后续临床研究设计和开展提供参考。
Glioma is the most common primary intracranial malignant tumor,and glioblastoma has the worst prognosis.In recent years,immunotherapy targeting immune checkpoints has shown promising results in various solid tumors,and has also become a potential breakthrough in the field of glioma treatment,which has attracted the attention of worldwide neurosurgeons and neuro-oncologists.This paper reviews the literature about immune checkpoint molecules and the clinical trials of immune checkpoint inhibitors,and briefly introduces the research status of immunotherapy in glioma.We hope to provide some references for the design and development of subsequent clinical studies of glioma immunotherapy in China.
作者
丁骁杰
陈弟
唐超
姚瑜
DING Xiao jie;CHEN Di;TANG Chao;YAO Yu(Department of Neurosurgery,Huashan Hospital,Fudan University,Shanghai 200040,China;Immunology Laboratory,Neurosurgical Institute of Fudan University,Shanghai 201206,China)
出处
《中国现代神经疾病杂志》
CAS
北大核心
2020年第2期96-104,共9页
Chinese Journal of Contemporary Neurology and Neurosurgery
基金
国家自然科学基金资助项目(项目编号:81372708)
国家重点研发计划项目(项目编号:91959112).
作者简介
通讯作者:姚瑜,Email:yu_yao@fudan.edu.cn
